S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35

Trevena Stock Forecast, Price & News

+0.07 (+5.69 %)
(As of 09/27/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.21 million shs
Average Volume2.79 million shs
Market Capitalization$213.86 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TRVN News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter.

Trevena logo

About Trevena

Trevena, Inc. engages in the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A. Rockman, Jonathan Violin, and Erin Whalen on November 9, 2007 and is headquartered in Chesterbrook, PA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$3.07 million
Book Value
$0.66 per share


Net Income
Net Margins




Market Cap
$213.86 million
Next Earnings Date
11/1/2021 (Estimated)


Overall MarketRank

1.98 out of 5 stars

Medical Sector

592nd out of 1,353 stocks

Pharmaceutical Preparations Industry

285th out of 666 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Trevena (NASDAQ:TRVN) Frequently Asked Questions

Is Trevena a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Trevena stock.
View analyst ratings for Trevena
or view top-rated stocks.

What stocks does MarketBeat like better than Trevena?

Wall Street analysts have given Trevena a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Trevena wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Trevena?

Trevena saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 14,830,000 shares, a decline of 16.0% from the July 29th total of 17,650,000 shares. Based on an average trading volume of 2,250,000 shares, the days-to-cover ratio is currently 6.6 days. Currently, 9.3% of the company's stock are short sold.
View Trevena's Short Interest

When is Trevena's next earnings date?

Trevena is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Trevena

How were Trevena's earnings last quarter?

Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings data on Thursday, August, 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.01. Trevena had a negative trailing twelve-month return on equity of 40.89% and a negative net margin of 1,194.62%.
View Trevena's earnings history

How has Trevena's stock been impacted by COVID-19 (Coronavirus)?

Trevena's stock was trading at $0.6984 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TRVN stock has increased by 86.1% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19

What price target have analysts set for TRVN?

2 brokerages have issued 12-month price targets for Trevena's stock. Their forecasts range from $6.00 to $6.00. On average, they expect Trevena's stock price to reach $6.00 in the next year. This suggests a possible upside of 361.5% from the stock's current price.
View analysts' price targets for Trevena
or view top-rated stocks among Wall Street analysts.

Who are Trevena's key executives?

Trevena's management team includes the following people:
  • Carrie L. Bourdow, President, Chief Executive Officer & Director
  • Barry Shin, Chief Financial Officer & Senior Vice President
  • Mark A. Demitrack, Chief Medical Officer & Senior Vice President
  • Angela Bagley, Vice President-Technical Operations
  • Michael J. Fossler, VP-Clinical Development & Quantitative Sciences

What other stocks do shareholders of Trevena own?

What is Trevena's stock symbol?

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Who are Trevena's major shareholders?

Trevena's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.79%), Vanguard Group Inc. (4.68%), Geode Capital Management LLC (1.65%), State Street Corp (1.62%), Northern Trust Corp (0.35%) and Nuveen Asset Management LLC (0.34%).
View institutional ownership trends for Trevena

Which major investors are selling Trevena stock?

TRVN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Cubist Systematic Strategies LLC, Citadel Advisors LLC, Goldman Sachs Group Inc., Group One Trading L.P., Jacobi Capital Management LLC, and Wells Fargo & Company MN.
View insider buying and selling activity for Trevena
or view top insider-selling stocks.

Which major investors are buying Trevena stock?

TRVN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and Northern Trust Corp.
View insider buying and selling activity for Trevena
or or view top insider-buying stocks.

How do I buy shares of Trevena?

Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Trevena's stock price today?

One share of TRVN stock can currently be purchased for approximately $1.30.

How much money does Trevena make?

Trevena has a market capitalization of $213.86 million and generates $3.07 million in revenue each year. The biopharmaceutical company earns $-29,370,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How many employees does Trevena have?

Trevena employs 25 workers across the globe.

What is Trevena's official website?

The official website for Trevena is www.trevena.com.

Where are Trevena's headquarters?

How can I contact Trevena?

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at [email protected].

This page was last updated on 9/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.